DEVELOPMENT OF NOVEL HYDROQUINONE-BASED SERCA INHIBITORS

新型氢醌 SERCA 抑制剂的开发

• 批准号: 7610397
• 负责人: Stefan Franz Paula
• 金额: $ 1.45万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7610397
• 关键词: Ca(2+)-Transporting ATPase; Chemotherapy-Oncologic Procedure; Computational Technique; Computer Retrieval of Information on Scientific Projects Database; Development; Endoplasmic Reticulum; Enzyme Inhibitor Drugs; Enzyme Inhibitors; Enzymes; Funding; Goals; Grant; Hydroquinones; Institution; Research; Research Personnel; Resources; Source; United States National Institutes of Health; base; hydroquinone; inhibitor/antagonist; novel; tool

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of the proposed research is to initiate the development of novel inhibitors of the enzyme sarco-endoplasmic reticulum calcium ATPase (SERCA) using a combination of experimental and computational techniques. Not only are SERCA inhibitors powerful tools for the study of the enzyme's function, but they are also believed to be of potential medicinal value for cancer chemotherapy.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 拟议研究的总体目标是使用实验和计算技术相结合，启动酶肌内质网钙ATP酶（SERCA）的新型抑制剂的开发。SERCA抑制剂不仅是研究酶功能的有力工具，而且被认为对癌症化疗具有潜在的药用价值。